Individuals in the tau PET cohort who were cognitively impaired (CDR ≥ 0.5) were included in Knight ADRC tau PET symptomatic AD subcohort (n = 55) (Supplementary Table 1). The gene discussed is MAPT; the disease is Alzheimer disease.